Increasing Chromatographic Performance of Acidic Peptides in RPLC-MS-based Assays with ACQUITY PREMIER featuring MaxPeak HPS Technology
Applications | 2020 | WatersInstrumentation
Metal‐ion mediated adsorption of acidic peptides during reversed‐phase liquid chromatography with mass spectrometry (RPLC‐MS) can cause peak tailing, reduced recovery and compromised assay reproducibility. These artifacts are especially critical in peptide mapping assays used for characterization and quality control of biopharmaceutical products, where detection of post-translational modifications and trace impurities is essential.
This application note evaluates ACQUITY PREMIER columns featuring MaxPeak HPS Technology as a solution to minimize analyte–surface interactions. The study compares conventional stainless‐steel columns to MaxPeak HPS columns for RPLC‐MS peptide mapping of a NIST monoclonal antibody (mAb) tryptic digest, focusing on sensitivity, tailing, recovery, reproducibility and method compatibility.
Samples: Waters NIST mAb tryptic digest standard, 0.2 mg/mL in water with 0.1 % FA.
Chromatography: Waters ACQUITY UPLC H-Class system with binary pump, ACQUITY PREMIER Peptide CSH C18 column (2.1 × 100 mm, 1.7 µm) versus standard CSH C18 column. Mobile phases: water/0.1 % formic acid (A), acetonitrile/0.1 % formic acid (B). Flow rate 0.2 mL/min, column temp 60 °C, sample temp 6 °C.
Detection: Waters SYNAPT XS high-resolution MS (ESI+; 50–2000 m/z) and ACQUITY QDa single-quadrupole MS (ESI+; 250–1250 m/z). Data processed in Empower 3 and UNIFI.
Peak Tailing Reduction: The PENNYK peptide (GFYPSDIAVEWESNGQPENNYK) tailing factor decreased from 5.53 on a conventional column to 1.15 on MaxPeak HPS, enabling clear resolution of native and deamidated species.
Increased Recovery: The T14 acidic peptide (VDNALQSGNSQESVTEQDSK) at 0.2 µg load was undetected on a standard column (90 % sequence coverage) but recovered on MaxPeak HPS with 94 % coverage.
Enhanced Response and Reproducibility: The T37 peptide showed a ten‐fold increase in peak height and four‐fold in area, with MS response variability (height RSD) reduced from 11.6 % to 1.1 % over three injections.
Improved Data Quality: Fragmentation spectra in MSE mode enabled unambiguous assignment of deamidation sites on resolved T37 species, increasing confidence in peptide identification.
Operational Robustness: Over 48 hr and repeated injections on a cleaned system, tailing factor RSD for the PENNYK peptide was 8.9 % on a conventional column versus 1.0 % on MaxPeak HPS, demonstrating stable performance without lengthy passivation.
Legacy Method Compatibility: Retention times and selectivity were conserved (slope = 1.00; intercept = -0.005) when comparing MaxPeak HPS to standard columns, facilitating method transfer with minimal revalidation.
Continued development of inert surface chemistries may further mitigate adsorption for diverse analytes. Integration of MaxPeak HPS columns into high-throughput bioanalysis pipelines and expansion to other metallic‐sensitive compounds are promising. Ongoing efforts to combine surface technologies with advanced MS acquisition modes will drive deeper characterization of complex biologics.
ACQUITY PREMIER columns featuring MaxPeak HPS Technology effectively minimize metal‐ion mediated adsorption of acidic peptides, delivering superior peak shape, increased recovery, greater reproducibility and retention time consistency. This enhancement supports reliable RPLC‐MS peptide mapping in biopharmaceutical development and manufacturing without compromising legacy method performance.
Consumables, HPLC, LC/TOF, LC/HRMS, LC/MS, LC/MS/MS, LC columns, LC/SQ
IndustriesProteomics
ManufacturerWaters
Summary
Significance of the Topic
Metal‐ion mediated adsorption of acidic peptides during reversed‐phase liquid chromatography with mass spectrometry (RPLC‐MS) can cause peak tailing, reduced recovery and compromised assay reproducibility. These artifacts are especially critical in peptide mapping assays used for characterization and quality control of biopharmaceutical products, where detection of post-translational modifications and trace impurities is essential.
Objectives and Overview
This application note evaluates ACQUITY PREMIER columns featuring MaxPeak HPS Technology as a solution to minimize analyte–surface interactions. The study compares conventional stainless‐steel columns to MaxPeak HPS columns for RPLC‐MS peptide mapping of a NIST monoclonal antibody (mAb) tryptic digest, focusing on sensitivity, tailing, recovery, reproducibility and method compatibility.
Methodology and Instrumentation
Samples: Waters NIST mAb tryptic digest standard, 0.2 mg/mL in water with 0.1 % FA.
Chromatography: Waters ACQUITY UPLC H-Class system with binary pump, ACQUITY PREMIER Peptide CSH C18 column (2.1 × 100 mm, 1.7 µm) versus standard CSH C18 column. Mobile phases: water/0.1 % formic acid (A), acetonitrile/0.1 % formic acid (B). Flow rate 0.2 mL/min, column temp 60 °C, sample temp 6 °C.
Detection: Waters SYNAPT XS high-resolution MS (ESI+; 50–2000 m/z) and ACQUITY QDa single-quadrupole MS (ESI+; 250–1250 m/z). Data processed in Empower 3 and UNIFI.
Main Results and Discussion
Peak Tailing Reduction: The PENNYK peptide (GFYPSDIAVEWESNGQPENNYK) tailing factor decreased from 5.53 on a conventional column to 1.15 on MaxPeak HPS, enabling clear resolution of native and deamidated species.
Increased Recovery: The T14 acidic peptide (VDNALQSGNSQESVTEQDSK) at 0.2 µg load was undetected on a standard column (90 % sequence coverage) but recovered on MaxPeak HPS with 94 % coverage.
Enhanced Response and Reproducibility: The T37 peptide showed a ten‐fold increase in peak height and four‐fold in area, with MS response variability (height RSD) reduced from 11.6 % to 1.1 % over three injections.
Improved Data Quality: Fragmentation spectra in MSE mode enabled unambiguous assignment of deamidation sites on resolved T37 species, increasing confidence in peptide identification.
Operational Robustness: Over 48 hr and repeated injections on a cleaned system, tailing factor RSD for the PENNYK peptide was 8.9 % on a conventional column versus 1.0 % on MaxPeak HPS, demonstrating stable performance without lengthy passivation.
Legacy Method Compatibility: Retention times and selectivity were conserved (slope = 1.00; intercept = -0.005) when comparing MaxPeak HPS to standard columns, facilitating method transfer with minimal revalidation.
Benefits and Practical Applications
- Higher sensitivity through improved recovery and sharper peaks.
- Enhanced assay reproducibility and robustness in peptide mapping.
- Reduced method development time and avoidance of corrosive passivation steps.
- Compatibility with existing RPLC‐MS workflows and legacy methods without additional additives.
Future Trends and Opportunities
Continued development of inert surface chemistries may further mitigate adsorption for diverse analytes. Integration of MaxPeak HPS columns into high-throughput bioanalysis pipelines and expansion to other metallic‐sensitive compounds are promising. Ongoing efforts to combine surface technologies with advanced MS acquisition modes will drive deeper characterization of complex biologics.
Conclusion
ACQUITY PREMIER columns featuring MaxPeak HPS Technology effectively minimize metal‐ion mediated adsorption of acidic peptides, delivering superior peak shape, increased recovery, greater reproducibility and retention time consistency. This enhancement supports reliable RPLC‐MS peptide mapping in biopharmaceutical development and manufacturing without compromising legacy method performance.
Reference
- Giddings JC, Eyring H. A Molecular Dynamic Theory of Chromatography. Journal of Physical Chemistry. 1955;59:416–421.
- Fornstedt T, Zhong G, Guiochon G. Peak Tailing and Slow Mass Transfer Kinetics in Nonlinear Chromatography. Journal of Chromatography A. 1996;742:55–68.
- Fornstedt T, Zhong G, Guiochon G. Peak Tailing and Mass Transfer Kinetics in Linear Chromatography. Journal of Chromatography A. 1996;741:1–12.
- Lauber M et al. Low Adsorption LC Technology Based on MaxPeak High Performance Surfaces. Waters White Paper 720006930EN. 2020.
- Birdsall R, Kellett J, Yu YQ, Chen W. Application of Mobile Phase Additives to Reduce Metal‐ion Mediated Adsorption of Non-phosphorylated Peptides in RPLC-MS-based Assays. Journal of Chromatography B. 2019;1126–1127:121773.
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.
Similar PDF
Peptide Mapping for Biotherapeutics
2023|Waters|Guides
Peptide Mapping for Biotherapeutics Strategies for Simplifying Protein Digestion A sponsored publication from Peptide Mapping Doesn’t Need to Be Complex Introducing PeptideWorks™ Tryptic Protein Digestion Kits PeptideWorks Tryptic Protein Digestion Kits uniquely deliver automatable, high efficiency, reproducible peptide maps in…
Key words
peptide, peptidetrypsin, trypsinmapping, mappingdigestion, digestionrapizyme, rapizymehps, hpsmaxpeak, maxpeakacquity, acquityprotein, proteinpeptideworks, peptideworkspremier, premiercqa, cqaproteins, proteinstryptic, trypticcan
The BioAccord System With ACQUITY Premier for Improved Peptide CQA Monitoring
2021|Waters|Applications
Application Note The BioAccord System With ACQUITY Premier for Improved Peptide CQA Monitoring Nilini Ranbaduge, Robert E. Birdsall, Ying Qing Yu, Weibin Chen Waters Corporation Abstract Peptide MAM is an LC-MS based assay for direct biotherapeutic product attribute analysis that…
Key words
bioaccord, bioaccordhps, hpsmaxpeak, maxpeakpremier, premiersurfaces, surfacesmam, mamacquity, acquitypeptide, peptideperformance, performanceacidic, acidicsystem, systemaspartic, aspartictechnology, technologyattribute, attributeassay
Improving Chromatographic Separations Of Biopharmaceuticals With MaxPeak High Performance Surfaces (HPS) Technology
2023|Waters|Brochures and specifications
Improving Chromatographic Separations Of Biopharmaceuticals With MaxPeak High Performance Surfaces (HPS) Technology Analytical Solutions Using MaxPeak High Performance Surfaces (HPS) Technology for Biopharmaceutical Therapeutics Biopharmaceutical therapeutics have consistently been the fastest growing segment within the pharmaceutical space and require advances…
Key words
premier, premieracquity, acquityglycan, glycanmaxpeak, maxpeaknucleotide, nucleotideculture, culturehps, hpspeptide, peptideintact, intactsystem, systembioaccord, bioaccordcolumn, columnread, readprotein, proteinglycans
Migrating Methods from the ACQUITY™ UPLC™ “Classic” System to the ACQUITY Premier System (FL)
2023|Waters|Applications
Application Note Migrating Methods from the ACQUITY™ UPLC™ “Classic” System to the ACQUITY Premier System (FL) Robert E. Birdsall, Kellen DeLaney, Pawel Bigos, Tatyana Friedman Waters Corporation Abstract Identifying improvement opportunities in pharmaceutical product lifecycle management is recommended as a…
Key words
acquity, acquityclassic, classicmigrating, migratingpremier, premieruplc, uplcsystem, systemmethods, methodsfrom, fromhps, hpsmaxpeak, maxpeaklifecycle, lifecycletailing, tailingaspartic, asparticlegacy, legacycontinually